PriceTargets.com logo

Mediclinic International - MDC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 484
  • Forecasted Upside: -2.60%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 496.90 As of 02/7/2023 01:30 PM ET
▼ -0.1 (-0.02%)

This chart shows the closing price for MDC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mediclinic International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDC

Analyst Price Target is GBX 484
▼ -2.60% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Mediclinic International in the last 3 months. The average price target is GBX 484, with a high forecast of GBX 504 and a low forecast of GBX 464. The average price target represents a -2.60% upside from the last price of GBX 496.90.

This chart shows the closing price for MDC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Mediclinic International. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/28/2022BarclaysDowngradeEqual WeightGBX 460 ➝ GBX 504
8/4/2022Berenberg BankReiterated RatingHoldGBX 464
6/21/2022Berenberg BankReiterated RatingHoldGBX 464
5/31/2022BarclaysBoost TargetOverweightGBX 385 ➝ GBX 460
10/29/2021BarclaysBoost TargetOverweightGBX 370 ➝ GBX 385
9/10/2021BarclaysBoost TargetOverweightGBX 365 ➝ GBX 370
8/26/2021HSBCUpgradeBuyGBX 280 ➝ GBX 340
7/22/2020BarclaysReiterated RatingEqual weight
7/8/2020Jefferies Financial GroupLower TargetBuyGBX 482 ➝ GBX 323
6/11/2020UBS GroupDowngradeNeutralGBX 400 ➝ GBX 320
5/14/2020HSBCUpgradeHoldGBX 270 ➝ GBX 260
4/14/2020HSBCLower TargetReduceGBX 310 ➝ GBX 270
1/21/2020Jefferies Financial GroupBoost TargetBuyGBX 457 ➝ GBX 482
12/18/2019BarclaysBoost TargetEqual weightGBX 360 ➝ GBX 400
11/29/2019Jefferies Financial GroupBoost TargetBuyGBX 422 ➝ GBX 457
11/26/2019UBS GroupDowngradeNeutralGBX 385 ➝ GBX 400
11/15/2019Jefferies Financial GroupReiterated RatingBuy
10/14/2019UBS GroupReiterated RatingBuyGBX 395 ➝ GBX 385
6/20/2019HSBCLower TargetHoldGBX 360 ➝ GBX 310
6/7/2019UBS GroupReiterated RatingBuyGBX 410 ➝ GBX 395
6/4/2019Bank of AmericaUpgradeNeutral
4/12/2019BarclaysLower TargetEqual weightGBX 460 ➝ GBX 410
1/16/2019HSBCLower TargetHoldGBX 390 ➝ GBX 360
1/7/2019JPMorgan Chase & Co.UpgradeOverweightGBX 480 ➝ GBX 394
10/25/2018HSBCUpgradeHoldGBX 540 ➝ GBX 390
10/18/2018BarclaysDowngradeEqual weightGBX 660 ➝ GBX 460
10/2/2018CitigroupUpgradeBuy
9/28/2018BarclaysLower TargetOverweightGBX 700 ➝ GBX 660
8/9/2018Credit Suisse GroupLower TargetNeutralGBX 660 ➝ GBX 550
8/7/2018BarclaysLower TargetOverweightGBX 751 ➝ GBX 700
4/13/2018BarclaysInitiated CoverageOverweightGBX 751
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Mediclinic International logo
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers specialist-orientated and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, 2 mental health facilities, and 453 theatres with approximately 11,538 inpatient beds in Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in the intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
Read More

Today's Range

Now: GBX 496.90
Low: 496.40
High: 497.60

50 Day Range

MA: GBX 497.05
Low: 495
High: 498.60

52 Week Range

Now: GBX 496.90
Low: 304.60
High: 503.50

Volume

2,381,893 shs

Average Volume

2,632,440 shs

Market Capitalization

£3.66 billion

P/E Ratio

2,160.43

Dividend Yield

0.60%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mediclinic International?

The following Wall Street analysts have issued reports on Mediclinic International in the last year: Barclays PLC, and Berenberg Bank.
View the latest analyst ratings for MDC.

What is the current price target for Mediclinic International?

2 Wall Street analysts have set twelve-month price targets for Mediclinic International in the last year. Their average twelve-month price target is GBX 484, suggesting a possible downside of 2.6%. Barclays PLC has the highest price target set, predicting MDC will reach GBX 504 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of GBX 464 for Mediclinic International in the next year.
View the latest price targets for MDC.

What is the current consensus analyst rating for Mediclinic International?

Mediclinic International currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MDC, but not buy more shares or sell existing shares.
View the latest ratings for MDC.

What other companies compete with Mediclinic International?

Other companies that are similar to Mediclinic International include Spire Healthcare Group, Hikma Pharmaceuticals, Dechra Pharmaceuticals, BTG and Abcam. Learn More about companies similar to Mediclinic International.

How do I contact Mediclinic International's investor relations team?

Mediclinic International's physical mailing address is 6th Floor 65 Gresham Street, LONDON, EC2V 7NQ, United Kingdom. The company's listed phone number is +44-20-79549600. The official website for Mediclinic International is www.mediclinic.com. Learn More about contacing Mediclinic International investor relations.